- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT01668498
Comparison of Two Preemptive Treatment Strategies of Panitumumab Mediated Skin Toxicity and Assessment of QoL in Patient With Ras-wt Colorectal Cancer
Comparison of Two Preemptive Treatment Strategies of Panitumumab Mediated Skin Toxicity and Assessment of Quality of Life in Patients With Ras-wildtype Colorectal Cancer
80 - 90 % of the patients treated with anti-EGFR antibodies (panitumumab or cetuximab) experience skin toxicity, mostly acne like skin rash.
A standardized treatment of skin rash is neither established as standard arm for clinical trials nor as guideline for the treatment of skin toxicity in clinical practice. While an improvement of QoL has been demonstrated for panitumumab and cetuximab in comparison to best supportive care the data basis for patient related outcomes regarding skin toxicity deriving from randomized trials is still small.
Recent surveys among German oncologist revealed that physicians are reluctant to use oral antibiotics as preemptive treatment . Only 19 out of 110 oncologists stated that they are thinking about using preemptive treatment in patients with acne-like skin rash.
Thus, in the present trial two main questions will be addressed:
(i) Can preemptive treatment with oral doxycycline be replaced by a sequential skin treatment strategy (i.e. local treatment with erythromycin followed by doxycycline in case of inefficacy = development of acne) without compromising treatment efficacy of skin toxicity treatment? (ii) Comparison of general and skin related QoL between both treatment arms.
Study Overview
Status
Conditions
Intervention / Treatment
Study Type
Enrollment (Actual)
Phase
- Phase 2
Contacts and Locations
Study Locations
-
-
-
Mannheim, Germany, 68167
- Universitätsklinikum Mannheim, III. Medizinische Klinik
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
Patients with wild-type RAS (KRAS and NRAS) status of metastatic colorectal cancer treatment with panitumumab according to label
- RAS wild-type tested in
- KRAS exon 2 (codons 12/13)
- KRAS exon 3 (codons 59/61)
- KRAS exon 4 (codons 117/146)
- NRAS exon 2 (codons 12/13)
- NRAS exon 3 (codons 59/61)
- NRAS exon 4 (codons 117/146)
- treatment with pre-emptive study medication shall begin the day before treatment start with panitumumab
- Willingness to cope with biweekly quality of life questionnaires
- Written Informed consent
- Aged at least 18 years
- ECOG Performance Status 0-2
- Life expectancy of at least 12 weeks
Adequate haematological, hepatic, renal and metabolic function parameters:
- Leukocytes > 3000/mm³
- ANC ≥ 1500/mm³
- Platelets ≥ 100,000/mm³
- Haemoglobin > 9 g/dl
- Serum creatinine ≤ 1.5 x ULN
- Bilirubin ≤ 1.5 x ULN
- GOT-GPT ≤ 2.5 x ULN (in case of liver metastases GOT / GPT ≤ 5 x ULN)
- AP ≤ 5 x ULN
- Magnesium, Calcium and potassium within normal ranges (may be substituted before study entry)
Exclusion criteria:
- Subject pregnant or breast feeding, or planning to become pregnant within 6 months after the end of treatment.
- Subject (male or female) is not willing to use highly effective methods of contraception (per institutional standard) during treatment and for 6 months (male or female) after the end of treatment (adequate: oral contraceptives, intrauterine device or barrier method in conjunction with spermicidal jelly).
- Serious concurrent diseases
- On-treatment participation in a clinical study in the period 30 days prior to inclusion
- Clinically significant cardiovascular disease in (incl. myocardial infarction, unstable angina, symptomatic congestive heart failure, serious uncontrolled cardiac arrhythmia) ≤ 1 year before enrolment.
- History of interstitial lung disease, e.g. pneumonitis or pulmonary fibrosis or evidence of interstitial lung disease on baseline chest CT scan.
- History of HIV infection.
- Other previous or concurrent malignancy (≤ 5 years prior to enrolment in study) except non-melanoma skin cancer or cervical carcinoma FIGO stage 0- 1 if the patient is continuously disease-free
- Known allergic reactions on panitumumab, doxycycline or erythromycin
- Previous treatment with anti-cancer agents directed against EGFR (e.g. cetuximab, panitumumab, erlotinib, gefitinib, lapatinib)
- Skin rash existing before or due to other reasons than panitumumab treatment
- Other dermatologic disease that may interfere with correct grading of panitumumab induced skin rash
- Parallel treatment with anti-tumor agents other than panitumumab
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Prevention
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Erythromycin
Experimental Arm (ARM A) skin- treatment: erythromycin cream 2% daily at bedtime doxycycline 100mg b.i.d.if skin toxicity CTC° ≥2 skin moisturizer daily at morning, sunscreen before going outdoors for 8 weeks
|
Comparison of efficacy of Arm A erythromycin cream 2% daily at bedtime (doxycycline 100mg b.i.d.if skin toxicity CTC° ≥2) and Arm B doxycycline 100mg b.i.d. in patients with Metastatic Colorectal cancer (Ras wild-type)being treated with panitumumab.
Other Names:
|
Active Comparator: Doxycyline
Standard Arm (ARM B) skin- treatment:doxycycline 100mg b.i.d.
skin moisturizer daily at morning, sunscreen before going outdoors for 8 weeks
|
Comparison of efficacy of Arm A erythromycin cream 2% daily at bedtime (doxycycline 100mg b.i.d.if skin toxicity CTC° ≥2) and Arm B doxycycline 100mg b.i.d. in patients with Metastatic Colorectal cancer (Ras wild-type)being treated with panitumumab.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Percentage of patients developing no skin toxicity ≥ grade 2
Time Frame: 8 weeks
|
Percentage of patients developing no skin toxicity ≥ grade 2 at any time during their first 8-weeks of treatment with panitumumab.
|
8 weeks
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Quality of life
Time Frame: 8 weeks
|
Quality of life will be assessed by standardized skin-related (DLQI) and global quality of life (EORTC QLQ C30. For correlation analyses between the different quality of life scores, the non-parametric test according to Spearman will preferably be applied. |
8 weeks
|
Assess Skin toxicity
Time Frame: 8 weeks
|
Assess different skin toxicity grading scales (i.e.
NCI CTC v. 4.0; WoMo score; MESTT)
|
8 weeks
|
Correlation between skin-related and global quality of life
Time Frame: 8 weeks
|
Description of correlation between skin-related and global quality of life using EORTC-QLQ C30 and SF-36.
|
8 weeks
|
late skin toxicity
Time Frame: from week 8 to 12
|
Describe the development of late skin toxicity after 8 weeks
|
from week 8 to 12
|
Skin-toxicity related dose reductions of panitumumab
Time Frame: 8 weeks
|
Rate of skin-toxicity induced dose reductions (including withdrawal) of panitumumab
|
8 weeks
|
Collaborators and Investigators
Sponsor
Investigators
- Principal Investigator: Melanie Kripp, Dr. med., III. Medizinische Klinik, Universitätsmedizin Mannheim
Publications and helpful links
Helpful Links
Study record dates
Study Major Dates
Study Start
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Estimate)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
- Digestive System Diseases
- Neoplasms
- Neoplasms by Site
- Gastrointestinal Neoplasms
- Digestive System Neoplasms
- Gastrointestinal Diseases
- Colonic Diseases
- Intestinal Diseases
- Intestinal Neoplasms
- Rectal Diseases
- Colorectal Neoplasms
- Molecular Mechanisms of Pharmacological Action
- Anti-Infective Agents
- Enzyme Inhibitors
- Gastrointestinal Agents
- Anti-Bacterial Agents
- Protein Synthesis Inhibitors
- Antiprotozoal Agents
- Antiparasitic Agents
- Antimalarials
- Erythromycin
- Erythromycin Estolate
- Erythromycin Ethylsuccinate
- Erythromycin stearate
- Doxycycline
Other Study ID Numbers
- AIO-LQ-0110
- 2010-022938-85 (EudraCT Number)
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Ras-wildtype Colorectal Cancer
-
University Health Network, TorontoCompletedColorectal Cancer | KRAS Wildtype | NRAS Wildtype | BRAF WildtypeCanada
-
Vanderbilt-Ingram Cancer CenterNational Cancer Institute (NCI); Calithera Biosciences, IncActive, not recruitingMetastatic Colorectal Cancer | Colorectal Cancer | RAS Wild Type Colorectal Cancer | Refractory Colorectal CancerUnited States
-
Beijing HospitalBethune Charitable FoundationRecruitingICE Study: Combination of Irinotecan Plus Cetuximab and Envafolimab as a Rechallenge Regimen in mCRCMetastatic Colorectal Cancer | MSS | RAS MutationChina
-
iOMEDICO AGAmgenActive, not recruitingMetastatic Colorectal Cancer | RAS Wild-typeGermany
-
AmgenCompletedWild-type RAS Metastatic Colorectal Cancer
-
University of Campania "Luigi Vanvitelli"CompletedMetastatic Colorectal Cancer | RAS Wild TypeItaly
-
M.D. Anderson Cancer CenterActive, not recruitingStage IV Colorectal Cancer | Stage IVA Colorectal Cancer | Stage IVB Colorectal Cancer | RAS Wild TypeUnited States
-
Azienda Unità Sanitaria Locale Reggio EmiliaIstituto Di Ricerche Farmacologiche Mario Negri; Istituto Nazionale Tumori...RecruitingMetastatic Colorectal Cancer | Colorectal Cancer | RAS MutationItaly
-
National Cancer Institute, NaplesRecruitingRas-mutated Metastatic Colorectal CancerItaly
-
PfizerBristol-Myers SquibbCompletedMSS | RAS-mutant Colorectal CancerUnited States, Spain, Belgium, United Kingdom, Netherlands
Clinical Trials on Erythromycin
-
Centre Hospitalier Universitaire de NiceUnknownEpidermolysis BullosaFrance
-
Beijing Children's HospitalUnknown
-
King Abdul Aziz Specialist HospitalCompleted
-
michal rollUnknownFAP-Familial Adenomatous PolyposisIsrael
-
The Catholic University of KoreaCompletedStomach Cancer | Subtotal GastrectomyKorea, Republic of
-
Prof Dr Jan TackTerminatedGastric MotilityBelgium
-
Canisius-Wilhelmina HospitalCompleted
-
PfizerCompleted
-
University of FloridaMetabolic Solutions Inc.TerminatedGastroparesisUnited States
-
MetroHealth Medical CenterTerminatedLength of Pregnancy Prolongation in HoursUnited States